The Breast Friends Podcast Ep. 7 | Dr. Daniel Hayes: The Future of Liquid Biopsy

The Breast Friends Podcast Ep. 7 | Dr. Daniel Hayes: The Future of Liquid Biopsy

How did liquid biopsy become one of the most important tools in modern oncology? In Episode 7 of The Breast Friends Podcast, Dr. Jason Mouabbi and Dr. Paolo Tarantino are joined by Dr. Daniel Hayes, Past President of ASCO and one of the pioneers behind tumor markers and liquid biopsy in breast cancer. From the mid-1980s breakthrough clinical discovery of CA 15-3 to the cutting-edge evolution of circulating tumor cells (CTCs), ctDNA, MRD, and multi-cancer early detection (MCED), Dr. Hayes shares the captivating behind-the-scenes stories, scientific milestones, and lessons that have shaped decades of breast cancer research. This conversation is more than an oncology history lesson. It's a deep dive into the future of precision medicine, the reality of tumor heterogeneity, and the mystery of cancer dormancy that will define the next generation of cancer care. 🎙️ Hosted by Drs. Jason A. Mouabbi & Paolo Tarantino ▶️ Watch on YouTube - https://youtu.be/PvguD4bXN-E 🎧 Listen on Spotify, Apple Podcasts, iHeartRadio, CastBox, and Amazon Music - https://linkin.bio/breastfriendspodcast 📺 As Mentioned in the Episode: Watch the historic interview featuring Dr. Daniel Hayes, Dr. Lawrence Einhorn, and John Cleland, the first patient ever cured of metastatic testicular cancer with platinum combination therapy: https://youtu.be/mKBQDSMInuI?si=YGvwlS-UfXlNvloP The Breast Friends Podcast is part of the Community Health Media Podcast Network, where meaningful conversations help patients, caregivers, advocates, and healthcare professionals learn from one another, one story at a time. #BreastCancer #Oncology #LiquidBiopsy #ctDNA #CTCs #PrecisionOncology #CancerResearch #MedicalOncology #ASCO #OncologyPodcast #MedEd

The Breast Friends Podcast Ep. 6 | HER2+ Breast Cancer Is Entering a New Era

The HER2-positive revolution isn't coming. It's here. In Episode 6 of The Breast Friends Podcast, Dr. Jason Mouabbi and Dr. Paolo Tarantino unpack the practice-changing data emerging from ESMO Breast 2026. From DESTINY-Breast11 and DESTINY-Breast05 to the growing role of HER2DX, ctDNA, MRI-guided treatment adaptation, and chemotherapy-free strategies, this conversation explores a fundamental shift in breast oncology: moving from treating every patient the same to delivering truly personalized care. Can we safely eliminate carboplatin? Can biomarkers tell us who needs less treatment? Is a chemotherapy-free future finally a reality for certain patients? The future of HER2-positive breast cancer is being written right now. 🎙️ Hosted by Drs. Jason A. Mouabbi & Paolo Tarantino ▶️ Watch on YouTube - https://youtu.be/WrvmVGEgoIA 🎧 Listen on Spotify, Apple Podcasts, iHeartRadio, CastBox and Amazon Music #BreastCancer #HER2Positive #Oncology #OncologyPodcast #ESMOBreast #CancerResearch #ClinicalTrials #PrecisionMedicine #MedicalOncology #MedEd #Enhertu #TDXd

The Breast Friends Podcast Ep. 5 | Dr. Hope Rugo: The Evolution of Breast Oncology

What shaped modern breast oncology and what comes next? From the pioneering HER2 breakthroughs to the recent innovation of ADCs and oral SERDs, Dr. Rugo provides a masterclass on the therapies that are changing the standard of care. The discussion also looks ahead, exploring the clinical utility of ctDNA monitoring and the critical importance of preserving quality of life in the metastatic setting. From HER2 breakthroughs and ADC innovation to oral SERDs, ctDNA monitoring, quality of life, and the future of metastatic breast cancer care, this conversation is a masterclass in where the field has been and where it’s heading next. This is oncology history, innovation, and the future all in one conversation. 🎙️ Hosted by Drs. Jason A. Mouabbi & Paolo Tarantino 👤 Featuring Dr. Hope Rugo ▶️ Watch on YouTube - https://youtu.be/IGbXzLpE-LY 🎧 Listen on Spotify, Apple Podcasts, iHeartRadio, CastBox and Amazon Music #BreastCancer #Oncology #OncologyPodcast #HopeRugo #CancerResearch #ClinicalTrials #PrecisionMedicine #MedicalOncology #MedEd #ADC

The Breast Friends Podcast Ep. 4 | The Future of Breast Cancer Treatment

What does the future of breast oncology look like? In Episode 4, Dr. Jason Mouabbi and Dr. Paolo Tarantino are joined by Professor Giuseppe Curigliano, Professor of Medical Oncology at the University of Milano, Head of the Experimental Therapeutics Program at the European Institute of Oncology, ESMO President-Elect, and Young Science Talent Scout, to forecast the next decade of breast cancer care. This conversation looks beyond current standards to the next frontier of breast oncology—from the evolution of ADCs and ctDNA to the emerging roles of bispecifics, radioligand therapy, and cancer vaccines. We’re mapping out where the science is heading and how it will redefine precision medicine in breast cancer! 🎧 Listen on Spotify, Apple Podcasts, iHeartRadio, CastBox and Amazon Music #BreastCancer #Oncology #OncologyPodcast #CancerResearch #ClinicalTrials #PrecisionMedicine #MedEd #MedicalOncology #ESMO #CancerInnovation

The Breast Friends Podcast Ep. 3 | Breast Cancer Trial Madness

👉 Cast your vote here: https://www.tinyurl.com/breastfriendsmadness It’s March Madness, the Breast Friends Madness way! In Episode 3, Dr. Jason Mouabbi and Dr. Paolo Tarantino are hitting the court to break down the heavy hitters of 2025 using our "Breast Friends Madness" bracket. Among the featured lineups are studies ranging from the practice-changing results of the DESTINY-Breast trials to the strategic shifts in SERENA-6, monarchE, and ASCENT-04. We’re scouting the data officially rewriting the playbook for HER2+, TNBC, and HR+ care. EVERY study in this bracket is a WIN for our patients. Let’s get ready to highlight the trials moving the field forward. ▶️ Watch on YouTube 🎧 Listen on Spotify, Apple Podcasts, iHeartRadio, CastBox & Amazon Music #BreastCancer #Oncology #OncologyPodcast #CancerResearch #ClinicalTrials #HER2Positive #TripleNegativeBreastCancer #MedEd #MedicalOncology